Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 4/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211406 | 0.82 | NOTUM (0.69) | NOTUMKDM4EMAPTRXRAGRIN1 | |
| SCHEMBL19211455 | 0.81 | NOTUM (0.71) | NOTUMKDM4EMAPTRXRAGRIN1 | |
| SCHEMBL28602472 | 0.81 | NOTUM (0.67) | NOTUMKDM4EMAPTRXRAGRIN1 | |
| SCHEMBL21792302 | 0.80 | NOTUM (0.71) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL21792036 | 0.80 | NOTUM (0.66) | NOTUMKDM4EMAPTRXRAGRIN1 | |
| SCHEMBL23451575 | 0.78 | NOTUM (1.00) | NOTUMKDM4EMAPTRXRAGRIN1 | |
| SCHEMBL19211446 | 0.78 | GRIN1 (0.72) | NOTUMRXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL21792045 | 0.78 | NOTUM (1.00) | NOTUMKDM4EMAPTKCNH2 | |
| SCHEMBL21776986 | 0.76 | NOTUM (0.70) | NOTUMKDM4EMAPTKCNH2 | |
| SCHEMBL28602470 | 0.75 | NOTUM (0.66) | NOTUMRXRAGRIN1GRIN2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885KDM4E 3907/4885MAPT 1431/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885KDM4E 4149/4885MAPT 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.